Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of metastatic prostatic adenocarcinoma
Receiving luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist therapy continuously for at least 1 year with anticipated lifelong therapy
Able to complete written surveys in English
You may not be if
More than 2 prior systemic treatment regimens utilized in addition to castration.
Clareo Health | Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
